Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer
Patients, Clinicians, Scientists
The Translational Research Centre in Onco-Hematology (CRTOH), coordinated by Professors Mikael Pittet and Olivier Michielin, is dedicated to promoting translational and interdisciplinary cancer research that has the potential to quickly benefit patients. This involves a close collaboration between clinicians and researchers, and a proximity with the patients. The Centre also aims to promote the training of the next generation of researchers and clinicians focusing on translational cancer research.
The CRTOH comprises 34 research groups and more than 300 collaborators. Our ongoing research efforts are centered around several key areas, including tumor immunology and immunotherapy, precision oncology, cell division and cancer, and cancer pharmacology.
Latest News
Immune 'hijacking' predicts cancer evolution
The promises of AI in terms of cancer treatment
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state
Pfizer Prize for a personalised therapeutic vaccine against cancer